Bluejay Diagnostics, Inc. Form 8-K Summary
Business Context and Reporting Period
Bluejay Diagnostics, Inc. (BJDX), an emerging growth company incorporated in Delaware, filed this Current Report on Form 8-K on April 7, 2025. The report details a material definitive agreement entered into on April 7, 2025, with certain existing holders of the Company's Class C warrants. The transaction closed on April 8, 2025.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $3.7 million generated from the exercise of existing warrants and the sale of new warrants.
- Transaction Costs: A financial advisory fee of approximately $385,000 was paid to Aegis Capital Corp.
- Shares Issued: 682,203 shares of Common Stock were issued at closing.
- Pre-funded Shares: 402,903 shares were pre-funded (excluding a nominal $0.0001 exercise price) to accommodate beneficial ownership limitations.
- Warrant Exercise Price Reduction: Existing warrant exercise price reduced from $16.30 to $3.42 per share.
- New Warrants: 1,085,106 new Class E warrants issued at a cost of $0.125 per warrant, with an exercise price of $3.42 and an expiration date of April 8, 2030.
Note: This filing does not provide standard periodic financial metrics such as revenue, net profit, operating cash flow, or total debt levels.
Material Changes
The primary material change is the restructuring of the Company's warrant obligations. Holders agreed to immediately exercise existing warrants at a significantly reduced price in exchange for new warrants. This action resulted in immediate capital infusion and a reduction in the outstanding exercise price for the warrant holders.
Outlook, Risks, and Contingencies
The Company agreed to file a registration statement to allow for the resale of shares issuable upon the exercise of the New Warrants. The New Warrants were issued in a private placement pursuant to Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D. No specific forward-looking guidance or risk factors beyond the standard terms of the warrant agreement were detailed in this specific filing text.
Key Facts for Investor Verification
- Verify the dilution impact of the 1,085,106 new Class E warrants and the 1,085,106 shares issued/pre-funded.
- Confirm the net cash proceeds after deducting the $385,000 advisory fee.
- Review the full text of the Inducement Letter Agreement (Exhibit 10.1) for specific beneficial ownership limitations and pre-funding terms.
- Monitor the filing of the registration statement for the resale of New Warrant shares.